OKYO Pharma Ltd - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by OKYO Pharma Ltd on March 19, 2026. The report discloses a transaction involving an executive officer rather than providing periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific insider trading event.
Material Changes
On March 19, 2026, Gary Jacob, Chief Development Officer and Director, acquired 30,980 ordinary shares of the Company on NASDAQ at a price of $1.59 per share. This transaction increased his total holdings to 108,920 shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document serves solely to furnish the news announcement regarding the share acquisition as Exhibit 99.1.
Investor Verification Checklist
- Verify the total share ownership of Gary Jacob post-transaction (108,920 shares).
- Confirm the transaction price of $1.59 per share against the NASDAQ closing price on March 19, 2026.
- Review the attached Exhibit 99.1 for the full text of the news announcement.
- Note that this filing does not contain updated financial statements or operational metrics.